Abstract. – In the treatment of depression fluoxetine [a selective serotonine reuptake inhibitor (SSRIs)] is a widely used drug in humans. The selectivity, efficacy, side effects and simplicity of dosage contributed to fluoxetine’s clinical acceptance. Several psychiatric disorders (many of them responsive to SSRIs) are present during pregnancy; up to 10% of pregnant women fulfill diagnostic criteria for major or minor depression with an even higher percentage developing postpartum depression. Therefore, significant numbers of women may be taking SSRIs while pregnant. Since fluoxetine’s safe use during pregnancy is not yet established and experimental studies inconclusive, we performed the present research in order to investigate the neurobehavioral effects produced in rats by prenatal exposure to fluoxetine (5 and 10 mg/kg/sc from day 13 to 20 of gestation) on cognitive functions, emotional reactivity and sexual performance.
Corresponding Author: Raffaele Cagiano, MD; e-mail: firstname.lastname@example.orgFree PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
R. Cagiano, P. Flace3, I. Bera1, L. Maries1, G. Cioca1, R. Sabatini4, V. Benagiano3, P. Auteri5, A. Marzullo6, D. Vermesan2, R. Stefanelli7, G. Ambrosi3
Neurofunctional effects in rats prenatally exposed to fluoxetine
Eur Rev Med Pharmacol Sci
Vol. 12 - N. 3